Last reviewed · How we verify
Selen
At a glance
| Generic name | Selen |
|---|---|
| Sponsor | Oslo University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies (PHASE2)
- Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab (PHASE1, PHASE2)
- Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. (PHASE4)
- SLM + Axitinib for Clear Cell RCC (PHASE1)
- A Study of Selenomethionine and Myo-inositol(SOLOWAYS_TM) in Patients With Autoimmune Thyroiditis Carrying the DIO2 Thr92Ala Polymorphism (NA)
- Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism (NA)
- Optimal Selenium for Bowel Polyps (OSCAR) (PHASE1)
- Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selen CI brief — competitive landscape report
- Selen updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI